Waters Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
11.9%projected annual EPS growth
Analyst Coverage
23analysts covering
FY Revenue (est.)
$6.5Bnext fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 3 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Organic Constant Currency Revenue Growth Quarterly700.0%Target: 6.5% to 8.0%
Adjusted Operating Margin Quarterly2,820.0%Target: EBITDA margin expansion via synergies
BDS Cost Synergies Realized AnnuallyTarget: $200 million
Watch Items
- Integration of BD's Biosciences and Diagnostic Solutions (BDS) businessTrigger: Achievement of $200 million in cost synergies and $290 million in revenue synergiesAction: Monitor quarterly segment margins and cross-selling revenue metrics
- China market recovery and biopharma spendingTrigger: Stabilization and double-digit organic growth in China end-marketsAction: Evaluate regional sales performance in quarterly earnings reports
Research as of 2 Sep 2026